{"href":"http://player.captivate.fm/services/oembed?url=http%3A%2F%2Fplayer.captivate.fm%2Fepisode%2Fcb6dcd5f-0d36-4c46-80f4-8533a9aa7847","version":"1.0","provider_name":"Captivate.FM","provider_url":"https://www.captivate.fm","width":600,"height":200,"type":"rich","html":"<iframe style=\"width: 100%; height: 200px;\" title=\"Key Presentations from the 64th American Society of Hematology (ASH) Annual Meeting: Chronic Lymphocytic Leukemia Edition\" frameborder=\"0\" scrolling=\"no\" allow=\"clipboard-write\" seamless src=\"http://player.captivate.fm/episode/cb6dcd5f-0d36-4c46-80f4-8533a9aa7847\"></iframe>","title":"Key Presentations from the 64th American Society of Hematology (ASH) Annual Meeting: Chronic Lymphocytic Leukemia Edition","description":"\n        <p>Dr John Allan from Weill Cornell Medicine in New York City discusses the most important chronic lymphocytic leukemia studies presented at ASH 2022.</p>\n\n<p>CME information and select publications <a href=\"http://www.researchtopractice.com/OncologyTodayPostASH23/CLL\" rel=\"nofollow\">here</a>.</p>\n      ","thumbnail_width":300,"thumbnail_height":300,"thumbnail_url":"https://artwork.captivate.fm/aba452ec-f086-4ce2-b39b-affc55a91dc6/cover.jpg"}